Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia

Protocol No
KURA-KO-MEN-007
Staff Member
Guru Subramanian Guru Murthy
Phase
I
Summary

This project is being done to determine the safe dose of an investigational new drug [ziftomenib] to be used in combination with other study drugs [cytarabine, daunorubicin, venetoclax, azacitidine] to treat your cancer
Objective
Study of ziftomenib in combination with venetoclax or chemotherapy for treatment of AML patients
Status
OPEN TO ACCRUAL
Categories
Cancer, Leukemia, Hematologic/Blood Related Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05735184